Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products and other therapies. Co.'s diabetes products include: Basaglar®, a long-acting human insulin analog for the treatment of diabetes; and Trajenta®, for the treatment of type 2 diabetes. Co.'s oncology products include: Alimta®, for treatment of patients with non-squamous cell histology and no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations.
When researching a stock like Eli Lilly, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from LLY Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for LLY stock — the real life supply and demand for the stock over time — and examines that data in different ways. One of those ways is to calculate a Simpe Moving Average ("SMA") by looking back a certain number of days. One of the most popular "longer look-backs" is the LLY 200 day moving average ("LLY 200 DMA"), while one of the most popular "shorter look-backs" is the LLY 50 day moving average ("LLY 50 DMA"). A chart showing both of these popular moving averages is shown on this page for Eli Lilly. |
Free LLY Email Alerts:
Video: Technical Analysis